FI90538B - Förfarande för framställning av terapeutiskt aktivt ranitidinsalt - Google Patents

Förfarande för framställning av terapeutiskt aktivt ranitidinsalt Download PDF

Info

Publication number
FI90538B
FI90538B FI893448A FI893448A FI90538B FI 90538 B FI90538 B FI 90538B FI 893448 A FI893448 A FI 893448A FI 893448 A FI893448 A FI 893448A FI 90538 B FI90538 B FI 90538B
Authority
FI
Finland
Prior art keywords
bismuth
ranitidine
methyl
water
complex
Prior art date
Application number
FI893448A
Other languages
English (en)
Finnish (fi)
Other versions
FI90538C (sv
FI893448A (sv
FI893448A0 (sv
Inventor
John Watson Clitherow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817098A external-priority patent/GB8817098D0/en
Priority claimed from GB898904686A external-priority patent/GB8904686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI893448A0 publication Critical patent/FI893448A0/sv
Publication of FI893448A publication Critical patent/FI893448A/sv
Application granted granted Critical
Publication of FI90538B publication Critical patent/FI90538B/sv
Publication of FI90538C publication Critical patent/FI90538C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (3)

1. Förfarande för framställning av terapeutiskt aktivt sait av ranitidin och ätminstone tre funktionella grupper för- 5 utom karboxylgruppen, som med ranitidin bildar ett sait, innehällande karboxy1syras vismutkomplex eller ett sädant salts soivat, kännetecknat därav, att ranitidin omsätts med vismutkarboxy1syrakomplex i vatten och det sä bildade salter aepareras frän lösningen. 10
2. Förfarande enligt patentkravet 1, kännetecknat därav, att N-[2-[[[5-[(dimetylamino)metyl]-2-fu-ranyl]metyl]tio]etyl]-N'-metyl-2-nitro-l,l-etendiamin-2-hydroxi-1,2,3-propant rikarboxy1 at-vismut(3*)kömpi ex och 15 dess soivat framställs.
3. Förfarande enligt patentkravet 1, kännetecknat därav, att N-[2-[[[5-[(dimetylamino)metyl]-2- furanyl]metyl]tio]etyl]-N’-metyl-2-nitro-l,1-etendiamin-20 [(R-R*R*)]-2,3-dihydroxibutandioat-vismut(3*)komplex och dess soivat framställs. li
FI893448A 1988-07-18 1989-07-17 Förfarande för framställning av terapeutiskt aktivt ranitidinsalt FI90538C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8817098 1988-07-18
GB888817098A GB8817098D0 (en) 1988-07-18 1988-07-18 Chemical compounds
GB8904686 1989-03-01
GB898904686A GB8904686D0 (en) 1989-03-01 1989-03-01 Chemical compounds

Publications (4)

Publication Number Publication Date
FI893448A0 FI893448A0 (sv) 1989-07-17
FI893448A FI893448A (sv) 1990-01-19
FI90538B true FI90538B (sv) 1993-11-15
FI90538C FI90538C (sv) 1994-02-25

Family

ID=26294175

Family Applications (1)

Application Number Title Priority Date Filing Date
FI893448A FI90538C (sv) 1988-07-18 1989-07-17 Förfarande för framställning av terapeutiskt aktivt ranitidinsalt

Country Status (35)

Country Link
US (1) US5008256A (sv)
JP (1) JP2523185B2 (sv)
KR (1) KR0122598B1 (sv)
CN (1) CN1022626C (sv)
AT (1) AT398200B (sv)
AU (1) AU632052B2 (sv)
BE (1) BE1003254A5 (sv)
CA (1) CA1332610C (sv)
CH (1) CH679582A5 (sv)
CY (1) CY1650A (sv)
DE (1) DE3923638C2 (sv)
DK (1) DK168381B1 (sv)
EG (1) EG19368A (sv)
ES (1) ES2014175A6 (sv)
FI (1) FI90538C (sv)
FR (1) FR2634122B1 (sv)
GB (1) GB2220937B (sv)
GR (1) GR1000431B (sv)
HK (1) HK61392A (sv)
HU (2) HU206104B (sv)
IE (1) IE61076B1 (sv)
IL (1) IL91005A (sv)
IT (1) IT1231481B (sv)
LU (2) LU88722I2 (sv)
MX (1) MX174145B (sv)
MY (1) MY104055A (sv)
NL (2) NL192604C (sv)
NO (2) NO176319C (sv)
NZ (1) NZ229958A (sv)
PL (1) PL162391B1 (sv)
PT (1) PT91188B (sv)
SE (1) SE468715B (sv)
SG (1) SG51992G (sv)
YU (1) YU47021B (sv)
ZW (1) ZW8689A1 (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009240D0 (en) * 1990-04-25 1990-06-20 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
ES2084174T3 (es) * 1990-07-20 1996-05-01 Tillotts Pharma Ag Productos y procesos para el tratamiento del conducto alimentario.
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
AU1671295A (en) * 1994-12-19 1996-07-10 Lauteral Limited Combinations of ranitidine hydrochloride-form 1 and bismuth compounds
HUP9900428A2 (hu) * 1995-01-26 1999-06-28 Nycomed Imaging A/S Bizmutvegyületek, ezeket tartalmazó diagnosztikai kontrasztanyag, ennek alkalmazása és ezt tartalmazó gyógyászati készítmény
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
EP1035192A1 (de) * 1999-01-26 2000-09-13 Stefan Graichen Additiv für einen Kühlschmierstoff
CN1102585C (zh) * 1999-04-28 2003-03-05 常州兰陵制药有限公司 雷尼替丁枸橼酸铋盐的制备方法
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
CN100402514C (zh) * 2006-08-01 2008-07-16 丽珠医药集团股份有限公司 一种制备枸橼酸铋雷尼替丁的方法
AU2007216671B2 (en) * 2007-07-09 2009-07-16 Cypress Pharmaceutical, Inc. Pleasant-tasting ranitidine formulation
CN102408398B (zh) * 2011-09-20 2012-12-05 江苏汉斯通药业有限公司 枸橼酸铋雷尼替丁的制备方法
US9731999B2 (en) 2011-09-23 2017-08-15 Iqbal Gill Chemical admixtures for hydraulic cements
ES2426539B1 (es) * 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
CN103896888B (zh) * 2014-03-28 2015-11-18 常州兰陵制药有限公司 枸橼酸铋雷尼替丁的制备方法
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
EP2942058A1 (en) 2014-05-09 2015-11-11 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
CN107382921A (zh) * 2017-07-28 2017-11-24 常州兰陵制药有限公司 制备枸橼酸铋雷尼替丁的方法
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
FR2531706A1 (fr) * 1982-08-13 1984-02-17 Sanofi Sa Benzamides, leurs sels, procede pour leur preparation et compositions pharmaceutiques les renfermant
BE905235A (fr) * 1986-08-05 1986-12-01 Hasunor Ag Ascorbates antagonistes des recepteurs h2 et leur procede de preparation.
IT1215325B (it) * 1987-01-07 1990-02-08 Barisintex Sa Composti antagonisti di recettori -h2 e procedimento per la loro preparazione.
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
FI90538C (sv) 1994-02-25
HK61392A (en) 1992-08-21
IT1231481B (it) 1991-12-07
CN1039419A (zh) 1990-02-07
JP2523185B2 (ja) 1996-08-07
AU632052B2 (en) 1992-12-17
NL970046I2 (nl) 1998-04-01
NO176319B (no) 1994-12-05
HUT52082A (en) 1990-06-28
SE8902550D0 (sv) 1989-07-17
BE1003254A5 (fr) 1992-02-11
IL91005A (en) 1994-10-07
PL162391B1 (pl) 1993-10-30
DK351789D0 (da) 1989-07-17
HU211173A9 (en) 1995-11-28
YU142789A (en) 1991-04-30
NO892936L (no) 1990-01-19
DE3923638C2 (de) 1995-11-23
DK168381B1 (da) 1994-03-21
GB8916288D0 (en) 1989-08-31
NO176319C (no) 1995-03-15
ZW8689A1 (en) 1990-02-21
GB2220937A (en) 1990-01-24
FI893448A (sv) 1990-01-19
LU87557A1 (fr) 1990-07-24
CH679582A5 (sv) 1992-03-13
CN1022626C (zh) 1993-11-03
NL970046I1 (nl) 1998-03-02
NO892936D0 (no) 1989-07-17
IE892309L (en) 1990-01-18
FR2634122A1 (fr) 1990-01-19
KR910002826A (ko) 1991-02-26
MX174145B (es) 1994-04-25
ATA172889A (de) 1994-02-15
SE8902550L (sv) 1990-01-19
GB2220937B (en) 1991-11-27
ES2014175A6 (es) 1990-06-16
GR1000431B (el) 1992-07-30
EG19368A (en) 1995-02-28
AT398200B (de) 1994-10-25
DK351789A (da) 1990-01-19
KR0122598B1 (ko) 1997-11-13
DE3923638A1 (de) 1990-03-01
LU88722I2 (fr) 1996-08-23
CA1332610C (en) 1994-10-18
NL192604B (nl) 1997-07-01
FI893448A0 (sv) 1989-07-17
CY1650A (en) 1992-12-11
IL91005A0 (en) 1990-02-09
NZ229958A (en) 1991-09-25
SG51992G (en) 1992-07-24
AU3817889A (en) 1990-01-18
NL8901840A (nl) 1990-02-16
IT8948196A0 (it) 1989-07-17
HU206104B (en) 1992-08-28
PT91188A (pt) 1990-02-08
NL192604C (nl) 1997-11-04
NO1998007I1 (no) 1998-02-05
SE468715B (sv) 1993-03-08
IE61076B1 (en) 1994-09-21
YU47021B (sh) 1994-11-15
GR890100454A (en) 1990-06-27
JPH02117684A (ja) 1990-05-02
MX16829A (es) 1993-10-01
US5008256A (en) 1991-04-16
FR2634122B1 (fr) 1993-11-19
MY104055A (en) 1993-10-30
PT91188B (pt) 1995-03-01

Similar Documents

Publication Publication Date Title
FI90538B (sv) Förfarande för framställning av terapeutiskt aktivt ranitidinsalt
KR0148480B1 (ko) 히스타민 h2-수용체 길항제의 염 및 용매화물
DE2306605A1 (de) Substituierte tricycloazaindole
DE1668930A1 (de) Neue Alkylaminopropanole und ihre Salze mit Saeuren,Verfahren zu ihrer Herstellung sowie therapeutische Mittel
JPH04217676A (ja) カルボン酸誘導体
US5229418A (en) Carboxylic acid derivatives
CH628346A5 (de) Verfahren zur herstellung neuer xanthinderivate.
RU2114857C1 (ru) Соли, образованные ранитидином и комплексным соединением висмута с карбоновой кислотой, и фармацевтический препарат
EP0399267A2 (de) 8-Substituierte 4-(Heterocyclylmethylamino)-chinoline, ihre Verwendung und daraus hergestellte Arzneimittel
EP0297593B1 (en) Treating agent for heart failure
EP0160173B1 (de) Benzothiazolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Arzneimittel
EP0439353B1 (en) Crystalline hydrochloride of new beta-lactam antibiotic and process therefor
CN104151261B (zh) 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
JPH0688974B2 (ja) ２−ピリジルアセタミド誘導体、その製法および用途
SK279173B6 (sk) Komplexná soľ ranitidínu, spôsob jej výroby a farm
SI8911427A (sl) Postopek za pripravo soli ranitidina z bizmutovimi kompleksi karboksilnih kislin
DE2347757B2 (de) Basisch substituierte 1,4-benzodioxane und deren pharmakologisch nicht giftige saeureadditionssalze und verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
BB Publication of examined application
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L137

Extension date: 20100713

FG Patent granted

Owner name: GLAXO GROUP LIMITED

MA Patent expired